Dadun Dadun cabecera universidad cabecera biblioteca
   (New user)
Help  | Contact  |  Castellano English  
 

Dadun > Depósito Académico > CIMA (Centro de Investigación Médica Aplicada) > Área de Ciencias Cardiovasculares > Aterosclerosis e inflamación > DA - CIMA - Cardiovasculares - Aterosclerosis e inflamación - Artículos de revista >

Alternativas farmacológicas a la transfusión sanguínea: ¿Qué hay de nuevo?
Authors: Paramo, J.A. (José Antonio)
Lecumberri, R. (Ramón)
Hernandez, M. (Milagros)
Rocha, E. (Eduardo)
Keywords: Transfusión sanguínea
Antifibrinolíticos
Vasopresina
Factor Vlla
Eritropoyetina
Issue Date: 2004
Publisher: Elsevier
Publisher version: http://bit.ly/KuwSeN
ISSN: 0025-7753
Citation: Paramo JA, Lecumberri R, Hernandez M, Rocha E. Alternativas farmacológicas a la transfusión sanguínea. ¿Qué hay de nuevo? Med Clin (Barc) 2004 Feb 21;122(6):231-236.
Abstract
Pharmacological approaches to reduce blood transfusion include the protease inhibitor aprotinin, lysine-analogue antifibrinolytics synthetic arginine-vasopressin derivatives (DDAVP) and recombinant factor VII (rfVIIa). These agents are known to prevent the need for blood after major surgery (cardiac, hepatic, and orthopaedic). Among the nonhemostatic agents erythropoietin (EPO) may be effective to reduce blood requirements in medical and surgical patients. Aprotinin is consistently effective in reducing blood transfusion in cardiac and hepatic surgical procedures, but there is little data to support its use in elective orthopaedic surgery. Antifibrinolytics show no evidence of efficacy in cardiac and hepatic surgery and its use is not warranted in orthopaedic surgery. Limited data suggest that DDAVP may be effective when a defect in platelet function is demonstrated. rFVIIa emerges as a promising haemostatic agent with proven benefit to reduce bleeding in haemophiliacs with inhibitors but might also be effective in patients with thrombocytopenia and thrombopathy, as well as in life-threatening hemorrhage in postsurgical patients. Ongoing studies will established its role a possible "universal haemostatic agent". Hematopoietic cytokines, such as EPO, may have a place to avoid blood transfusion in a variety of clinical conditions, including cancer and critically ill patients.
Permanent link: http://hdl.handle.net/10171/22855
Appears in Collections:DA - CUN - Hematología y Hemoterapia - Artículos de revista
DA - CIMA - Cardiovasculares - Aterosclerosis e inflamación - Artículos de revista

Files in This Item:
File:  MedClin2004_122231.pdf
Description: 
Size:  1,77 MB
Format:  Adobe PDF
 View / Open 

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.